3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
49
Letrozole
42
Fulvestrant
42
Paclitaxel
38
pembrolizumab
34
Magnetic Resonance Spectroscopy
31
Carboplatin
31
ribociclib
26
Trastuzumab
26
Biopsy
26
exemestane
23
Anastrozole
23
Capecitabine
22
palbociclib
21
pertuzumab
20
Tamoxifen
19
trastuzumab deruxtecan
18
abemaciclib
18
Cyclophosphamide
17
Taxes
15
Radiotherapy
14
130-nm albumin-bound paclitaxel
12
elacestrant
11
Docetaxel
11
sacituzumab govitecan
9
olaparib
9
Standard of Care
9
Radiation
9
Goserelin
9
Gemcitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Breast
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled